Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to progressing their clinical programs.
Management did not provide specific guidance for future quarters.
The focus remains on advancing the clinical pipeline.
Kodiak Sciences reported a loss per share of $0.33, but did not disclose revenue figures. The stock fell by 6.10%, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to navigate its clinical pipeline without specific targets.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UGI CORP NEW
Nov 11, 2019